Last updated
NAD+ and 5-Amino-1MQ both show up under the longevity-and-metabolism banner, and neither is actually a peptide — both are small molecules catalogued here for their metabolic relevance. They approach the same theme, cellular NAD+, from opposite directions: one is the cofactor itself, the other blocks an enzyme that drains its precursors.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | NAD+ | 5-Amino-1MQ |
|---|---|---|
| What it is | A coenzyme (dinucleotide) — not a peptide | A small-molecule enzyme inhibitor — not a peptide |
| Strategy | Supply the NAD+ cofactor directly | Inhibit NNMT to preserve NAD+ / methyl-donor pools |
| Direct target | Serves as substrate/cofactor for sirtuins, PARPs, redox enzymes | Nicotinamide N-methyltransferase (NNMT) |
| Research focus | Mitochondrial energy, sirtuin signaling, DNA repair, aging | Adipose-tissue metabolism, sarcopenia (muscle aging) |
| Rationale | NAD+ declines with age — restore it | NNMT wastes nicotinamide and SAM — block it upstream |
| Evidence stage | Research reagent / investigational therapeutic | Preclinical |
| FDA approval | None | None |
NAD+ (nicotinamide adenine dinucleotide) is the workhorse cofactor at the center of the aging conversation. Every cell uses it to carry electrons through energy metabolism and to power two enzyme families that matter for longevity — sirtuins, which depend on it to regulate stress resistance and gene expression, and PARPs, which consume it during DNA repair. Cellular NAD+ falls with age, and the direct strategy is simply to restore it, either as NAD+ itself or through its precursors.
5-Amino-1MQ comes at the same pool from upstream. It selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide — using up both nicotinamide (a NAD+ salvage precursor) and SAM (the cell’s main methyl donor). By blocking NNMT, 5-Amino-1MQ is studied in preclinical work to preserve those NAD+ and methyl-donor pools, with the metabolic readouts appearing in adipose tissue and aging muscle. So the contrast is clean: NAD+ is direct replacement of the cofactor; 5-Amino-1MQ is an attempt to stop the leak that depletes it. Both are small molecules — not peptides — grouped in this catalog for their metabolic-longevity relevance, and neither is FDA-approved.
Two approaches to the same target, cellular NAD+, at different points in the pathway. NAD+ supplies the cofactor directly and sits at the heart of mitochondrial, sirtuin, and DNA-repair biology; 5-Amino-1MQ works upstream, inhibiting the NNMT enzyme that consumes NAD+ precursors and methyl donors, with a preclinical focus on fat and muscle. Neither is a peptide, and neither is FDA-approved — NAD+ is used as a research reagent and studied therapeutically, while 5-Amino-1MQ remains preclinical. This page is a research and educational reference.
NAD+ is the coenzyme itself, supplied directly to support energy metabolism, sirtuins, and DNA repair. 5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied to preserve NAD+ and methyl-donor (SAM) pools upstream rather than supplying NAD+ directly. Neither is a peptide.
Both center on cellular NAD+. NAD+ replaces the cofactor directly; 5-Amino-1MQ blocks NNMT, an enzyme that consumes nicotinamide (a NAD+ precursor) and SAM, so inhibiting it is studied as a way to preserve those pools.
No. NAD+ is a dinucleotide coenzyme and 5-Amino-1MQ is a small-molecule enzyme inhibitor. Both are catalogued alongside peptides for their metabolic and longevity relevance, but neither is a peptide.
No. NAD+ is used as a research reagent and studied as an investigational therapeutic; 5-Amino-1MQ is a preclinical research compound. Neither is FDA-approved. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between NAD+ and 5-Amino-1MQ — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.